MO805: Combination of Conventional Haemodialysis with Haemoperfusion: Does it Provide any Benefits to Haemodialysis Patients?
Abstract BACKGROUND AND AIMS Conventional haemodialysis (HD) with low-flux membranes does not provide adequate middle molecular weight (MMW) clearance of uremic toxins [1]. The potential for better removal of parathyroid hormone (PTH) and β2-microglobulin (β2M) was investigated using a combination o...
Gespeichert in:
| Veröffentlicht in: | Nephrology, dialysis, transplantation dialysis, transplantation, 2022-05, Vol.37 (Supplement_3) |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_3 |
| container_start_page | |
| container_title | Nephrology, dialysis, transplantation |
| container_volume | 37 |
| creator | Sonikian, Makrouhi Velentza, Aikaterinh Chiras, Theodoros Skarakis, Jacob Biblaki, Dimitra Dagkounaki, Paraskevi Karakou, Eugenia Trakas, Nikolaos Barbatsi, Aggeliki Martsoukou, Maria |
| description | Abstract
BACKGROUND AND AIMS
Conventional haemodialysis (HD) with low-flux membranes does not provide adequate middle molecular weight (MMW) clearance of uremic toxins [1]. The potential for better removal of parathyroid hormone (PTH) and β2-microglobulin (β2M) was investigated using a combination of low-flux HD and haemoperfusion (HP) (HD + HP).
METHOD
A total of 16 stable HD male patients, free of infections, malignancies or haematological disorders, under usual medications for anaemia and hyperparathyroidism, treated with low-flux polysulfone membranes, were randomized into two groups: group A (GA) included eight patients under HD + HP and group B (GΒ) included eight patients under HD only. In GA patients, a type HA130 HP cartridge was connected in parallel to the dialyzer, once a week for the first month, once every 2 weeks for the second month and once a month for the next 4 months. A third group C (GC) was also studied, consisting of eight males undergoing online haemodiafiltration (OL-HDF). In all three groups, serum β2M and iPTH levels were determined at months 0 and 6, before (preD) and after (postD) the mid-week session.
RESULTS
Serum preD-β2M levels were similar in groups A and B at month 0 (44.1 ± 8.6 versus 34.6 ± 16.2 mg/L; P = NS) and at month 6 (46.1 ± 7.6 versus 41.1 ± 18.9 mg/L; P = NS). In GC, preD–β2M values were lower compared with GA at month 0 (31.1 ± 4.2 mg/L; P = .008) and at month 6 (33.8 ± 6.82 mg/L; P = .02), and postD–β2M values decreased significantly at month 0 (7.4 ± 1.9 mg/L; P < .001) and at month 6 (9.9 ± 3.8 mg/L; P < 0.001). The reduction was maintained, with no difference between month 0 and month 6. An improvement/decrease in β2M values was observed between month 0 and month 6 only in GA (–5.8 ± 7. 2 versus 1.8 ± 5 mg/L; P = .03) but not in GB. PreD–iPTH values did not differ between groups A, B and C at month 0 (623 ± 432 versus 434 ± 350 versus 710 ± 286 pg/mL, respectively; P = NS) and at month 6 (758 ± 550 versus 383 ± 186 versus 559 ± 296 pg/mL, respectively; P = NS). PostD–iPTH values showed a decrease at month 6 in GA (from 758 ± 550 to 514 ± 474 pg/mL; P = .04) but not in GB and a mild decrease in GC (from 559 ± 296 to 363 ± 295 pg/mL; P = .05), with a marginal reduction improvement between month 0 and month 6 in GC (41 ± 55 versus 196 ± 87 pg/mL; P = .046).
CONCLUSION
OL-HDF is obviously the most effective method for the elimination of MMW uremic toxins [2]. Interestingly, the combination HD + HP seems |
| doi_str_mv | 10.1093/ndt/gfac082.003 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ndt_gfac082_003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ndt/gfac082.003</oup_id><sourcerecordid>10.1093/ndt/gfac082.003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c753-9e8de27c557ccd43655cf5439980e85db1a18bd1ed5fcb08d61e60e875fbd9fd3</originalsourceid><addsrcrecordid>eNqFkM1PAjEQxRujiYievfZssjDd0t0uF6P4gQkGDtw33XaqNdCS7YLh4P9uCZy8eJq8mffeJD9CbhkMGFR86E03_LBKg8wHAPyM9NiogCznUpyTXnKwDARUl-Qqxi8AqPKy7JGf97kEMaaTsG6cV50LngabpN-hPyi1olOF62CcWu2ji_TbdZ_H1QZbu43JM6ZPASN1HV20YecMUuX39BE9WtdF2oU_FYv0J7XH-2tyYdUq4s1p9sny5Xk5mWaz-evb5GGW6VLwrEJpMC-1EKXWZsQLIbQVI15VElAK0zDFZGMYGmF1A9IUDIt0KYVtTGUN75PhsVa3IcYWbb1p3Vq1-5pBfYBXJ3j1CV6d4KXE3TERtpt_zb87UXSc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>MO805: Combination of Conventional Haemodialysis with Haemoperfusion: Does it Provide any Benefits to Haemodialysis Patients?</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Sonikian, Makrouhi ; Velentza, Aikaterinh ; Chiras, Theodoros ; Skarakis, Jacob ; Biblaki, Dimitra ; Dagkounaki, Paraskevi ; Karakou, Eugenia ; Trakas, Nikolaos ; Barbatsi, Aggeliki ; Martsoukou, Maria</creator><creatorcontrib>Sonikian, Makrouhi ; Velentza, Aikaterinh ; Chiras, Theodoros ; Skarakis, Jacob ; Biblaki, Dimitra ; Dagkounaki, Paraskevi ; Karakou, Eugenia ; Trakas, Nikolaos ; Barbatsi, Aggeliki ; Martsoukou, Maria</creatorcontrib><description>Abstract
BACKGROUND AND AIMS
Conventional haemodialysis (HD) with low-flux membranes does not provide adequate middle molecular weight (MMW) clearance of uremic toxins [1]. The potential for better removal of parathyroid hormone (PTH) and β2-microglobulin (β2M) was investigated using a combination of low-flux HD and haemoperfusion (HP) (HD + HP).
METHOD
A total of 16 stable HD male patients, free of infections, malignancies or haematological disorders, under usual medications for anaemia and hyperparathyroidism, treated with low-flux polysulfone membranes, were randomized into two groups: group A (GA) included eight patients under HD + HP and group B (GΒ) included eight patients under HD only. In GA patients, a type HA130 HP cartridge was connected in parallel to the dialyzer, once a week for the first month, once every 2 weeks for the second month and once a month for the next 4 months. A third group C (GC) was also studied, consisting of eight males undergoing online haemodiafiltration (OL-HDF). In all three groups, serum β2M and iPTH levels were determined at months 0 and 6, before (preD) and after (postD) the mid-week session.
RESULTS
Serum preD-β2M levels were similar in groups A and B at month 0 (44.1 ± 8.6 versus 34.6 ± 16.2 mg/L; P = NS) and at month 6 (46.1 ± 7.6 versus 41.1 ± 18.9 mg/L; P = NS). In GC, preD–β2M values were lower compared with GA at month 0 (31.1 ± 4.2 mg/L; P = .008) and at month 6 (33.8 ± 6.82 mg/L; P = .02), and postD–β2M values decreased significantly at month 0 (7.4 ± 1.9 mg/L; P < .001) and at month 6 (9.9 ± 3.8 mg/L; P < 0.001). The reduction was maintained, with no difference between month 0 and month 6. An improvement/decrease in β2M values was observed between month 0 and month 6 only in GA (–5.8 ± 7. 2 versus 1.8 ± 5 mg/L; P = .03) but not in GB. PreD–iPTH values did not differ between groups A, B and C at month 0 (623 ± 432 versus 434 ± 350 versus 710 ± 286 pg/mL, respectively; P = NS) and at month 6 (758 ± 550 versus 383 ± 186 versus 559 ± 296 pg/mL, respectively; P = NS). PostD–iPTH values showed a decrease at month 6 in GA (from 758 ± 550 to 514 ± 474 pg/mL; P = .04) but not in GB and a mild decrease in GC (from 559 ± 296 to 363 ± 295 pg/mL; P = .05), with a marginal reduction improvement between month 0 and month 6 in GC (41 ± 55 versus 196 ± 87 pg/mL; P = .046).
CONCLUSION
OL-HDF is obviously the most effective method for the elimination of MMW uremic toxins [2]. Interestingly, the combination HD + HP seems to be more effective than low-flux HD alone [3], and it could be useful for specific patient cases in daily clinical practice.</description><identifier>ISSN: 0931-0509</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/gfac082.003</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Nephrology, dialysis, transplantation, 2022-05, Vol.37 (Supplement_3)</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Sonikian, Makrouhi</creatorcontrib><creatorcontrib>Velentza, Aikaterinh</creatorcontrib><creatorcontrib>Chiras, Theodoros</creatorcontrib><creatorcontrib>Skarakis, Jacob</creatorcontrib><creatorcontrib>Biblaki, Dimitra</creatorcontrib><creatorcontrib>Dagkounaki, Paraskevi</creatorcontrib><creatorcontrib>Karakou, Eugenia</creatorcontrib><creatorcontrib>Trakas, Nikolaos</creatorcontrib><creatorcontrib>Barbatsi, Aggeliki</creatorcontrib><creatorcontrib>Martsoukou, Maria</creatorcontrib><title>MO805: Combination of Conventional Haemodialysis with Haemoperfusion: Does it Provide any Benefits to Haemodialysis Patients?</title><title>Nephrology, dialysis, transplantation</title><description>Abstract
BACKGROUND AND AIMS
Conventional haemodialysis (HD) with low-flux membranes does not provide adequate middle molecular weight (MMW) clearance of uremic toxins [1]. The potential for better removal of parathyroid hormone (PTH) and β2-microglobulin (β2M) was investigated using a combination of low-flux HD and haemoperfusion (HP) (HD + HP).
METHOD
A total of 16 stable HD male patients, free of infections, malignancies or haematological disorders, under usual medications for anaemia and hyperparathyroidism, treated with low-flux polysulfone membranes, were randomized into two groups: group A (GA) included eight patients under HD + HP and group B (GΒ) included eight patients under HD only. In GA patients, a type HA130 HP cartridge was connected in parallel to the dialyzer, once a week for the first month, once every 2 weeks for the second month and once a month for the next 4 months. A third group C (GC) was also studied, consisting of eight males undergoing online haemodiafiltration (OL-HDF). In all three groups, serum β2M and iPTH levels were determined at months 0 and 6, before (preD) and after (postD) the mid-week session.
RESULTS
Serum preD-β2M levels were similar in groups A and B at month 0 (44.1 ± 8.6 versus 34.6 ± 16.2 mg/L; P = NS) and at month 6 (46.1 ± 7.6 versus 41.1 ± 18.9 mg/L; P = NS). In GC, preD–β2M values were lower compared with GA at month 0 (31.1 ± 4.2 mg/L; P = .008) and at month 6 (33.8 ± 6.82 mg/L; P = .02), and postD–β2M values decreased significantly at month 0 (7.4 ± 1.9 mg/L; P < .001) and at month 6 (9.9 ± 3.8 mg/L; P < 0.001). The reduction was maintained, with no difference between month 0 and month 6. An improvement/decrease in β2M values was observed between month 0 and month 6 only in GA (–5.8 ± 7. 2 versus 1.8 ± 5 mg/L; P = .03) but not in GB. PreD–iPTH values did not differ between groups A, B and C at month 0 (623 ± 432 versus 434 ± 350 versus 710 ± 286 pg/mL, respectively; P = NS) and at month 6 (758 ± 550 versus 383 ± 186 versus 559 ± 296 pg/mL, respectively; P = NS). PostD–iPTH values showed a decrease at month 6 in GA (from 758 ± 550 to 514 ± 474 pg/mL; P = .04) but not in GB and a mild decrease in GC (from 559 ± 296 to 363 ± 295 pg/mL; P = .05), with a marginal reduction improvement between month 0 and month 6 in GC (41 ± 55 versus 196 ± 87 pg/mL; P = .046).
CONCLUSION
OL-HDF is obviously the most effective method for the elimination of MMW uremic toxins [2]. Interestingly, the combination HD + HP seems to be more effective than low-flux HD alone [3], and it could be useful for specific patient cases in daily clinical practice.</description><issn>0931-0509</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkM1PAjEQxRujiYievfZssjDd0t0uF6P4gQkGDtw33XaqNdCS7YLh4P9uCZy8eJq8mffeJD9CbhkMGFR86E03_LBKg8wHAPyM9NiogCznUpyTXnKwDARUl-Qqxi8AqPKy7JGf97kEMaaTsG6cV50LngabpN-hPyi1olOF62CcWu2ji_TbdZ_H1QZbu43JM6ZPASN1HV20YecMUuX39BE9WtdF2oU_FYv0J7XH-2tyYdUq4s1p9sny5Xk5mWaz-evb5GGW6VLwrEJpMC-1EKXWZsQLIbQVI15VElAK0zDFZGMYGmF1A9IUDIt0KYVtTGUN75PhsVa3IcYWbb1p3Vq1-5pBfYBXJ3j1CV6d4KXE3TERtpt_zb87UXSc</recordid><startdate>20220503</startdate><enddate>20220503</enddate><creator>Sonikian, Makrouhi</creator><creator>Velentza, Aikaterinh</creator><creator>Chiras, Theodoros</creator><creator>Skarakis, Jacob</creator><creator>Biblaki, Dimitra</creator><creator>Dagkounaki, Paraskevi</creator><creator>Karakou, Eugenia</creator><creator>Trakas, Nikolaos</creator><creator>Barbatsi, Aggeliki</creator><creator>Martsoukou, Maria</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20220503</creationdate><title>MO805: Combination of Conventional Haemodialysis with Haemoperfusion: Does it Provide any Benefits to Haemodialysis Patients?</title><author>Sonikian, Makrouhi ; Velentza, Aikaterinh ; Chiras, Theodoros ; Skarakis, Jacob ; Biblaki, Dimitra ; Dagkounaki, Paraskevi ; Karakou, Eugenia ; Trakas, Nikolaos ; Barbatsi, Aggeliki ; Martsoukou, Maria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c753-9e8de27c557ccd43655cf5439980e85db1a18bd1ed5fcb08d61e60e875fbd9fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sonikian, Makrouhi</creatorcontrib><creatorcontrib>Velentza, Aikaterinh</creatorcontrib><creatorcontrib>Chiras, Theodoros</creatorcontrib><creatorcontrib>Skarakis, Jacob</creatorcontrib><creatorcontrib>Biblaki, Dimitra</creatorcontrib><creatorcontrib>Dagkounaki, Paraskevi</creatorcontrib><creatorcontrib>Karakou, Eugenia</creatorcontrib><creatorcontrib>Trakas, Nikolaos</creatorcontrib><creatorcontrib>Barbatsi, Aggeliki</creatorcontrib><creatorcontrib>Martsoukou, Maria</creatorcontrib><collection>CrossRef</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sonikian, Makrouhi</au><au>Velentza, Aikaterinh</au><au>Chiras, Theodoros</au><au>Skarakis, Jacob</au><au>Biblaki, Dimitra</au><au>Dagkounaki, Paraskevi</au><au>Karakou, Eugenia</au><au>Trakas, Nikolaos</au><au>Barbatsi, Aggeliki</au><au>Martsoukou, Maria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MO805: Combination of Conventional Haemodialysis with Haemoperfusion: Does it Provide any Benefits to Haemodialysis Patients?</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><date>2022-05-03</date><risdate>2022</risdate><volume>37</volume><issue>Supplement_3</issue><issn>0931-0509</issn><eissn>1460-2385</eissn><abstract>Abstract
BACKGROUND AND AIMS
Conventional haemodialysis (HD) with low-flux membranes does not provide adequate middle molecular weight (MMW) clearance of uremic toxins [1]. The potential for better removal of parathyroid hormone (PTH) and β2-microglobulin (β2M) was investigated using a combination of low-flux HD and haemoperfusion (HP) (HD + HP).
METHOD
A total of 16 stable HD male patients, free of infections, malignancies or haematological disorders, under usual medications for anaemia and hyperparathyroidism, treated with low-flux polysulfone membranes, were randomized into two groups: group A (GA) included eight patients under HD + HP and group B (GΒ) included eight patients under HD only. In GA patients, a type HA130 HP cartridge was connected in parallel to the dialyzer, once a week for the first month, once every 2 weeks for the second month and once a month for the next 4 months. A third group C (GC) was also studied, consisting of eight males undergoing online haemodiafiltration (OL-HDF). In all three groups, serum β2M and iPTH levels were determined at months 0 and 6, before (preD) and after (postD) the mid-week session.
RESULTS
Serum preD-β2M levels were similar in groups A and B at month 0 (44.1 ± 8.6 versus 34.6 ± 16.2 mg/L; P = NS) and at month 6 (46.1 ± 7.6 versus 41.1 ± 18.9 mg/L; P = NS). In GC, preD–β2M values were lower compared with GA at month 0 (31.1 ± 4.2 mg/L; P = .008) and at month 6 (33.8 ± 6.82 mg/L; P = .02), and postD–β2M values decreased significantly at month 0 (7.4 ± 1.9 mg/L; P < .001) and at month 6 (9.9 ± 3.8 mg/L; P < 0.001). The reduction was maintained, with no difference between month 0 and month 6. An improvement/decrease in β2M values was observed between month 0 and month 6 only in GA (–5.8 ± 7. 2 versus 1.8 ± 5 mg/L; P = .03) but not in GB. PreD–iPTH values did not differ between groups A, B and C at month 0 (623 ± 432 versus 434 ± 350 versus 710 ± 286 pg/mL, respectively; P = NS) and at month 6 (758 ± 550 versus 383 ± 186 versus 559 ± 296 pg/mL, respectively; P = NS). PostD–iPTH values showed a decrease at month 6 in GA (from 758 ± 550 to 514 ± 474 pg/mL; P = .04) but not in GB and a mild decrease in GC (from 559 ± 296 to 363 ± 295 pg/mL; P = .05), with a marginal reduction improvement between month 0 and month 6 in GC (41 ± 55 versus 196 ± 87 pg/mL; P = .046).
CONCLUSION
OL-HDF is obviously the most effective method for the elimination of MMW uremic toxins [2]. Interestingly, the combination HD + HP seems to be more effective than low-flux HD alone [3], and it could be useful for specific patient cases in daily clinical practice.</abstract><pub>Oxford University Press</pub><doi>10.1093/ndt/gfac082.003</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0931-0509 |
| ispartof | Nephrology, dialysis, transplantation, 2022-05, Vol.37 (Supplement_3) |
| issn | 0931-0509 1460-2385 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_ndt_gfac082_003 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | MO805: Combination of Conventional Haemodialysis with Haemoperfusion: Does it Provide any Benefits to Haemodialysis Patients? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A09%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MO805:%20Combination%20of%20Conventional%20Haemodialysis%20with%20Haemoperfusion:%20Does%20it%20Provide%20any%20Benefits%20to%20Haemodialysis%20Patients?&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=Sonikian,%20Makrouhi&rft.date=2022-05-03&rft.volume=37&rft.issue=Supplement_3&rft.issn=0931-0509&rft.eissn=1460-2385&rft_id=info:doi/10.1093/ndt/gfac082.003&rft_dat=%3Coup_cross%3E10.1093/ndt/gfac082.003%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ndt/gfac082.003&rfr_iscdi=true |